Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the significance of his findings when combining an anti-CTLA-4 and anti-PD-1 in patients with multiple myeloma. He sought out to find whether these 2 drugs could be combined safely after an autologous stem cell transplant.
Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the significance of his findings when combining an anti-CTLA-4 and anti-PD-1 in patients with multiple myeloma. He sought out to find whether these 2 drugs could be combined safely after an autologous stem cell transplant.
The findings from this trial demonstrated the combination suppressed T-regulatory cells and could be combined safely.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma
March 26th 2024During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Read More
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
March 22nd 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Read More